Shopping Cart 0
Cart Subtotal
USD 0

Emergent BioSolutions Inc (EBS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Emergent BioSolutions Inc (Emergent) is a life sciences company. It focuses on protecting and enhancing life by providing specialized products to governments and healthcare providers. The company develops specialty products targeting public health threats and emerging infectious diseases. It's product portfolio includes vaccines and antibody therapeutics with focus on infectious diseases, autoimmune diseases and cancer. It uses multiple platform technologies, including the MVAtor and Emergard for delivery of its products. Its marketed products include BioThrax (anthrax vaccine adsorbed); WinRho SDF (Rho(D) immune globulin intravenous; (RSDL) reactive skin decontamination lotion; and HepaGam B for the treatment of hepatitis B. Emergent also has a developmental pipeline of candidates targeting dengue and other influenza infections. The company distributes its products in the US and Canada through its commercial sales forces and third party distributors. Emergent is headquartered in Rockville, Maryland, the US.

Emergent BioSolutions Inc (EBS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Emergent BioSolutions Inc, Medical Devices Deals, 2012 to YTD 2018 11

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deal Details 15

Asset Purchase 15

Emergent BioSolutions Acquires ACAM2000 Business from Sanofi 15

Emergent Biosolutions Acquires Raxibacumab from GSK 17

Emergent BioSolutions Acquires Portfolio of Antibiotics from Evolva Holding 19

PaxVax Acquires Vivotif from Crucell 21

Emergent BioSolutions Completes Acquisition Of Healthcare Protective Products Division Of Bracco Diagnostics For USD 26 Million 22

Venture Financing 24

PaxVax Raises USD50 Million in Venture Debt Financing 24

PaxVax Raises USD12 Million in Extended Series B Financing 25

PaxVax Raises USD 6 Million In Venture Financing 26

PaxVax Raises USD 22 Million In Series B Financing 27

Private Equity 28

Cerberus Capital Invests USD105 Million in PaxVax 28

Partnerships 29

CEPI Enters into Partnership with Profectus BioSciences and Emergent BioSolutions 29

CEPI Enters into Collaboration with Profectus BioSciences and Emergent BioSolutions 30

Emergent BioSolutions Enters into Agreement with BARDA 31

PaxVax and TerahVax Korea Enter into Distribution Agreement 32

Emergent BioSolutions Enters into Agreement with Biomedical Advanced Research and Development Authority 33

Emergent BioSolutions Enters into Agreement with Biomedical Advanced Research and Development Authority 34

PaxVax Enters into Distribution Agreement with Seqirus 35

Emergent BioSolutions Partners with Biomedical Advanced Research and Development Authority 36

Valneva Enters into Distribution Agreement with PaxVax 37

Soligenix Expands its Development Agreement with Emergent BioSolutions 38

PaxVax Enters into Distribution Agreement with BioCSL 39

PaxVax Enters into Distribution Agreement with Novartis 40

PaxVax Enters into Distribution Agreement with Valneva 41

Emergent BioSolutions Signs Agreement with Oxford University, GlaxoSmithKline and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate 42

Licensing Agreements 44

Emergent BioSolutions Enters into Licensing Agreement with Valneva 44

PaxVax Enters into Licensing Agreement with National Institutes of Health 45

Emergent BioSolutions Enters into Licensing Agreement with Integrated BioTherapeutics 46

PaxVax Enters into Licensing Agreement with Leukocare 47

Emergent BioSolutions Enters into Licensing Agreement with Ligand Pharma 48

Emergent BioSolutions Amends Licensing Agreement with MorphoSys for ES-414 49

Valneva Enters into Research Licensing Agreement with Emergent BioSolutions for EB66 Cell Line 51

PaxVax Enters into Licensing Agreement with University Of California, San Diego 52

Emergent BioSolutions Enters Into Licensing Agreement With VaxInnate For Pandemic Influenza Vaccine 53

Equity Offering 54

Emergent BioSolutions Completes Spin-Off of Aptevo Therapeutics 54

Emergent BioSolutions Files Registration Statement For Public Offering Of Securities For USD 180 Million 55

Debt Offering 56

Emergent BioSolutions Completes Private Placement Of Notes Due 2021 For USD 250 Million 56

Asset Transactions 58

ProMetic Life Sciences Acquires Plasma Collection Center in Canada from Emergent BioSolutions 58

Prokarium Acquires Typhella From Emergent BioSolutions 59

Acquisition 60

Emergent BioSolutions Acquires Adapt Pharma for USD735 Million 60

Emergent BioSolutions Acquires PaxVax from Cerberus Capital Management for USD270 Million 62

Emergent BioSolutions Acquires Unither Virology from United Therapeutics 64

Emergent BioSolutions Completes Acquisition Of Cangene For USD 222 Million 65

Emergent BioSolutions Inc-Key Competitors 67

Emergent BioSolutions Inc-Key Employees 68

Emergent BioSolutions Inc-Locations And Subsidiaries 69

Head Office 69

Other Locations & Subsidiaries 69

Joint Venture 71

Recent Developments 72

Strategy And Business Planning 72

Sep 24, 2018: Emergent BioSolutions expands manufacturing capability with ABEC dual purpose single-use microbial fermentation / mammalian cell culture systems 72

Jun 07, 2018: Emergent BioSolutions Announces USD 50 Million Expansion of Baltimore Fill/Finish Facility 73

May 10, 2017: Emergent BioSolutions Unveils Its Expanded Center for Innovation in Advanced Development and Manufacturing in Baltimore 74

Financial Announcements 76

Aug 02, 2018: Emergent BioSolutions reports financial results for second quarter and six months of 2018 76

May 03, 2018: Emergent BioSolutions Reports First Quarter 2018 Financial Results 79

Feb 22, 2018: Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2017 Financial Results 82

Jan 08, 2018: Emergent BioSolutions Announces Preliminary 2017 Financial Results and Provides 2018 Financial Outlook 85

Nov 02, 2017: Emergent BioSolutions Reports Third Quarter and Nine Months 2017 Financial Results; Raises Calendar Year 2017 Guidance 86

Aug 03, 2017: Emergent BioSolutions Reports Second Quarter and Six Months 2017 Financial Results; Reaffirms Calendar Year 2017 Guidance 89

May 04, 2017: Emergent BioSolutions Reports First Quarter 2017 Financial Results; Reaffirms 2017 Guidance 92

Feb 23, 2017: Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2016 Financial Results; Reaffirms 2017 Guidance and Provides 2020 Goals 94

Jan 09, 2017: Emergent BioSolutions Announces Preliminary 2016 Financial Results and Provides 2017 Financial Outlook 97

Corporate Communications 98

Mar 26, 2018: Emergent BioSolutions Announces Executive Management Changes That Enhance Execution of Company's Growth Strategy 98

Government and Public Interest 99

Feb 13, 2017: Emergent BioSolutions Receives BARDA Task Order Valued at Up to USD 30.5 Million to Develop Viral Hemorrhagic Fever Therapeutics 99

Product News 100

Sep 18, 2017: HHS partners to develop first intranasal treatment for cyanide poisoning 100

Clinical Trials 101

Jan 04, 2018: Emergent BioSolutions Initiates Phase 2 Clinical Study to Evaluate FLU-IGIV to Treat Serious Influenza A Infection 101

Other Significant Developments 102

Aug 09, 2018: Ebola virus experts discover powerful, new approach for future therapeutics 102

Appendix 104

Methodology 104

About GlobalData 104

Contact Us 104

Disclaimer 104


List Of Figure

List of Figures

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Emergent BioSolutions Inc, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Emergent BioSolutions Inc, Deals By Therapy Area, 2012 to YTD 2018 11

Emergent BioSolutions Inc, Medical Devices Deals, 2012 to YTD 2018 12

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Emergent BioSolutions Acquires ACAM2000 Business from Sanofi 16

Emergent Biosolutions Acquires Raxibacumab from GSK 18

Emergent BioSolutions Acquires Portfolio of Antibiotics from Evolva Holding 20

PaxVax Acquires Vivotif from Crucell 22

Emergent BioSolutions Completes Acquisition Of Healthcare Protective Products Division Of Bracco Diagnostics For USD 26 Million 23

PaxVax Raises USD50 Million in Venture Debt Financing 25

PaxVax Raises USD12 Million in Extended Series B Financing 26

PaxVax Raises USD 6 Million In Venture Financing 27

PaxVax Raises USD 22 Million In Series B Financing 28

Cerberus Capital Invests USD105 Million in PaxVax 29

CEPI Enters into Partnership with Profectus BioSciences and Emergent BioSolutions 30

CEPI Enters into Collaboration with Profectus BioSciences and Emergent BioSolutions 31

Emergent BioSolutions Enters into Agreement with BARDA 32

PaxVax and TerahVax Korea Enter into Distribution Agreement 33

Emergent BioSolutions Enters into Agreement with Biomedical Advanced Research and Development Authority 34

Emergent BioSolutions Enters into Agreement with Biomedical Advanced Research and Development Authority 35

PaxVax Enters into Distribution Agreement with Seqirus 36

Emergent BioSolutions Partners with Biomedical Advanced Research and Development Authority 37

Valneva Enters into Distribution Agreement with PaxVax 38

Soligenix Expands its Development Agreement with Emergent BioSolutions 39

PaxVax Enters into Distribution Agreement with BioCSL 40

PaxVax Enters into Distribution Agreement with Novartis 41

PaxVax Enters into Distribution Agreement with Valneva 42

Emergent BioSolutions Signs Agreement with Oxford University, GlaxoSmithKline and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate 43

Emergent BioSolutions Enters into Licensing Agreement with Valneva 45

PaxVax Enters into Licensing Agreement with National Institutes of Health 46

Emergent BioSolutions Enters into Licensing Agreement with Integrated BioTherapeutics 47

PaxVax Enters into Licensing Agreement with Leukocare 48

Emergent BioSolutions Enters into Licensing Agreement with Ligand Pharma 49

Emergent BioSolutions Amends Licensing Agreement with MorphoSys for ES-414 50

Valneva Enters into Research Licensing Agreement with Emergent BioSolutions for EB66 Cell Line 52

PaxVax Enters into Licensing Agreement with University Of California, San Diego 53

Emergent BioSolutions Enters Into Licensing Agreement With VaxInnate For Pandemic Influenza Vaccine 54

Emergent BioSolutions Completes Spin-Off of Aptevo Therapeutics 55

Emergent BioSolutions Files Registration Statement For Public Offering Of Securities For USD 180 Million 56

Emergent BioSolutions Completes Private Placement Of Notes Due 2021 For USD 250 Million 57

ProMetic Life Sciences Acquires Plasma Collection Center in Canada from Emergent BioSolutions 59

Prokarium Acquires Typhella From Emergent BioSolutions 60

Emergent BioSolutions Acquires Adapt Pharma for USD735 Million 61

Emergent BioSolutions Acquires PaxVax from Cerberus Capital Management for USD270 Million 63

Emergent BioSolutions Acquires Unither Virology from United Therapeutics 65

Emergent BioSolutions Completes Acquisition Of Cangene For USD 222 Million 66

Emergent BioSolutions Inc, Key Competitors 68

Emergent BioSolutions Inc, Key Employees 69

Emergent BioSolutions Inc, Other Locations 70

Emergent BioSolutions Inc, Subsidiaries 70

Emergent BioSolutions Inc, Joint Venture 72

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Emergent BioSolutions Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Emergent BioSolutions Inc (Emergent) is a life sciences company. It focuses on protecting and enhancing life by providing specialized products to governments and healthcare providers. The company develops specialty products targeting public health threats and emerging infectious diseases. It's product portfolio includes vaccines and antibody therapeutics with focus on infectious diseases, autoimmune diseases and cancer. It uses multiple platform technologies, including the MVAtor and Emergard for delivery of its products. Its marketed products include BioThrax (anthrax vaccine adsorbed); WinRho SDF (Rho(D) immune globulin intravenous; (RSDL) reactive skin decontamination lotion; and HepaGam B for the treatment of hepatitis B. Emergent also has a developmental pipeline of candidates targeting dengue and other influenza infections. The company distributes its products in the US and Canada through its commercial sales forces and third party distributors. Emergent is headquartered in Rockville, Maryland, the US.

Emergent BioSolutions Inc (EBS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 6

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Emergent BioSolutions Inc, Medical Devices Deals, 2012 to YTD 2018 11

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deal Details 15

Asset Purchase 15

Emergent BioSolutions Acquires ACAM2000 Business from Sanofi 15

Emergent Biosolutions Acquires Raxibacumab from GSK 17

Emergent BioSolutions Acquires Portfolio of Antibiotics from Evolva Holding 19

PaxVax Acquires Vivotif from Crucell 21

Emergent BioSolutions Completes Acquisition Of Healthcare Protective Products Division Of Bracco Diagnostics For USD 26 Million 22

Venture Financing 24

PaxVax Raises USD50 Million in Venture Debt Financing 24

PaxVax Raises USD12 Million in Extended Series B Financing 25

PaxVax Raises USD 6 Million In Venture Financing 26

PaxVax Raises USD 22 Million In Series B Financing 27

Private Equity 28

Cerberus Capital Invests USD105 Million in PaxVax 28

Partnerships 29

CEPI Enters into Partnership with Profectus BioSciences and Emergent BioSolutions 29

CEPI Enters into Collaboration with Profectus BioSciences and Emergent BioSolutions 30

Emergent BioSolutions Enters into Agreement with BARDA 31

PaxVax and TerahVax Korea Enter into Distribution Agreement 32

Emergent BioSolutions Enters into Agreement with Biomedical Advanced Research and Development Authority 33

Emergent BioSolutions Enters into Agreement with Biomedical Advanced Research and Development Authority 34

PaxVax Enters into Distribution Agreement with Seqirus 35

Emergent BioSolutions Partners with Biomedical Advanced Research and Development Authority 36

Valneva Enters into Distribution Agreement with PaxVax 37

Soligenix Expands its Development Agreement with Emergent BioSolutions 38

PaxVax Enters into Distribution Agreement with BioCSL 39

PaxVax Enters into Distribution Agreement with Novartis 40

PaxVax Enters into Distribution Agreement with Valneva 41

Emergent BioSolutions Signs Agreement with Oxford University, GlaxoSmithKline and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate 42

Licensing Agreements 44

Emergent BioSolutions Enters into Licensing Agreement with Valneva 44

PaxVax Enters into Licensing Agreement with National Institutes of Health 45

Emergent BioSolutions Enters into Licensing Agreement with Integrated BioTherapeutics 46

PaxVax Enters into Licensing Agreement with Leukocare 47

Emergent BioSolutions Enters into Licensing Agreement with Ligand Pharma 48

Emergent BioSolutions Amends Licensing Agreement with MorphoSys for ES-414 49

Valneva Enters into Research Licensing Agreement with Emergent BioSolutions for EB66 Cell Line 51

PaxVax Enters into Licensing Agreement with University Of California, San Diego 52

Emergent BioSolutions Enters Into Licensing Agreement With VaxInnate For Pandemic Influenza Vaccine 53

Equity Offering 54

Emergent BioSolutions Completes Spin-Off of Aptevo Therapeutics 54

Emergent BioSolutions Files Registration Statement For Public Offering Of Securities For USD 180 Million 55

Debt Offering 56

Emergent BioSolutions Completes Private Placement Of Notes Due 2021 For USD 250 Million 56

Asset Transactions 58

ProMetic Life Sciences Acquires Plasma Collection Center in Canada from Emergent BioSolutions 58

Prokarium Acquires Typhella From Emergent BioSolutions 59

Acquisition 60

Emergent BioSolutions Acquires Adapt Pharma for USD735 Million 60

Emergent BioSolutions Acquires PaxVax from Cerberus Capital Management for USD270 Million 62

Emergent BioSolutions Acquires Unither Virology from United Therapeutics 64

Emergent BioSolutions Completes Acquisition Of Cangene For USD 222 Million 65

Emergent BioSolutions Inc-Key Competitors 67

Emergent BioSolutions Inc-Key Employees 68

Emergent BioSolutions Inc-Locations And Subsidiaries 69

Head Office 69

Other Locations & Subsidiaries 69

Joint Venture 71

Recent Developments 72

Strategy And Business Planning 72

Sep 24, 2018: Emergent BioSolutions expands manufacturing capability with ABEC dual purpose single-use microbial fermentation / mammalian cell culture systems 72

Jun 07, 2018: Emergent BioSolutions Announces USD 50 Million Expansion of Baltimore Fill/Finish Facility 73

May 10, 2017: Emergent BioSolutions Unveils Its Expanded Center for Innovation in Advanced Development and Manufacturing in Baltimore 74

Financial Announcements 76

Aug 02, 2018: Emergent BioSolutions reports financial results for second quarter and six months of 2018 76

May 03, 2018: Emergent BioSolutions Reports First Quarter 2018 Financial Results 79

Feb 22, 2018: Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2017 Financial Results 82

Jan 08, 2018: Emergent BioSolutions Announces Preliminary 2017 Financial Results and Provides 2018 Financial Outlook 85

Nov 02, 2017: Emergent BioSolutions Reports Third Quarter and Nine Months 2017 Financial Results; Raises Calendar Year 2017 Guidance 86

Aug 03, 2017: Emergent BioSolutions Reports Second Quarter and Six Months 2017 Financial Results; Reaffirms Calendar Year 2017 Guidance 89

May 04, 2017: Emergent BioSolutions Reports First Quarter 2017 Financial Results; Reaffirms 2017 Guidance 92

Feb 23, 2017: Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2016 Financial Results; Reaffirms 2017 Guidance and Provides 2020 Goals 94

Jan 09, 2017: Emergent BioSolutions Announces Preliminary 2016 Financial Results and Provides 2017 Financial Outlook 97

Corporate Communications 98

Mar 26, 2018: Emergent BioSolutions Announces Executive Management Changes That Enhance Execution of Company's Growth Strategy 98

Government and Public Interest 99

Feb 13, 2017: Emergent BioSolutions Receives BARDA Task Order Valued at Up to USD 30.5 Million to Develop Viral Hemorrhagic Fever Therapeutics 99

Product News 100

Sep 18, 2017: HHS partners to develop first intranasal treatment for cyanide poisoning 100

Clinical Trials 101

Jan 04, 2018: Emergent BioSolutions Initiates Phase 2 Clinical Study to Evaluate FLU-IGIV to Treat Serious Influenza A Infection 101

Other Significant Developments 102

Aug 09, 2018: Ebola virus experts discover powerful, new approach for future therapeutics 102

Appendix 104

Methodology 104

About GlobalData 104

Contact Us 104

Disclaimer 104


List Of Figure

List of Figures

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

Emergent BioSolutions Inc, Medical Devices Deals, 2012 to YTD 2018 12


List Of Table

List of Tables

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

Emergent BioSolutions Inc, Deals By Therapy Area, 2012 to YTD 2018 11

Emergent BioSolutions Inc, Medical Devices Deals, 2012 to YTD 2018 12

Emergent BioSolutions Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13

Emergent BioSolutions Acquires ACAM2000 Business from Sanofi 16

Emergent Biosolutions Acquires Raxibacumab from GSK 18

Emergent BioSolutions Acquires Portfolio of Antibiotics from Evolva Holding 20

PaxVax Acquires Vivotif from Crucell 22

Emergent BioSolutions Completes Acquisition Of Healthcare Protective Products Division Of Bracco Diagnostics For USD 26 Million 23

PaxVax Raises USD50 Million in Venture Debt Financing 25

PaxVax Raises USD12 Million in Extended Series B Financing 26

PaxVax Raises USD 6 Million In Venture Financing 27

PaxVax Raises USD 22 Million In Series B Financing 28

Cerberus Capital Invests USD105 Million in PaxVax 29

CEPI Enters into Partnership with Profectus BioSciences and Emergent BioSolutions 30

CEPI Enters into Collaboration with Profectus BioSciences and Emergent BioSolutions 31

Emergent BioSolutions Enters into Agreement with BARDA 32

PaxVax and TerahVax Korea Enter into Distribution Agreement 33

Emergent BioSolutions Enters into Agreement with Biomedical Advanced Research and Development Authority 34

Emergent BioSolutions Enters into Agreement with Biomedical Advanced Research and Development Authority 35

PaxVax Enters into Distribution Agreement with Seqirus 36

Emergent BioSolutions Partners with Biomedical Advanced Research and Development Authority 37

Valneva Enters into Distribution Agreement with PaxVax 38

Soligenix Expands its Development Agreement with Emergent BioSolutions 39

PaxVax Enters into Distribution Agreement with BioCSL 40

PaxVax Enters into Distribution Agreement with Novartis 41

PaxVax Enters into Distribution Agreement with Valneva 42

Emergent BioSolutions Signs Agreement with Oxford University, GlaxoSmithKline and NIAID for the Production of an MVA Ebola Zaire Vaccine Candidate 43

Emergent BioSolutions Enters into Licensing Agreement with Valneva 45

PaxVax Enters into Licensing Agreement with National Institutes of Health 46

Emergent BioSolutions Enters into Licensing Agreement with Integrated BioTherapeutics 47

PaxVax Enters into Licensing Agreement with Leukocare 48

Emergent BioSolutions Enters into Licensing Agreement with Ligand Pharma 49

Emergent BioSolutions Amends Licensing Agreement with MorphoSys for ES-414 50

Valneva Enters into Research Licensing Agreement with Emergent BioSolutions for EB66 Cell Line 52

PaxVax Enters into Licensing Agreement with University Of California, San Diego 53

Emergent BioSolutions Enters Into Licensing Agreement With VaxInnate For Pandemic Influenza Vaccine 54

Emergent BioSolutions Completes Spin-Off of Aptevo Therapeutics 55

Emergent BioSolutions Files Registration Statement For Public Offering Of Securities For USD 180 Million 56

Emergent BioSolutions Completes Private Placement Of Notes Due 2021 For USD 250 Million 57

ProMetic Life Sciences Acquires Plasma Collection Center in Canada from Emergent BioSolutions 59

Prokarium Acquires Typhella From Emergent BioSolutions 60

Emergent BioSolutions Acquires Adapt Pharma for USD735 Million 61

Emergent BioSolutions Acquires PaxVax from Cerberus Capital Management for USD270 Million 63

Emergent BioSolutions Acquires Unither Virology from United Therapeutics 65

Emergent BioSolutions Completes Acquisition Of Cangene For USD 222 Million 66

Emergent BioSolutions Inc, Key Competitors 68

Emergent BioSolutions Inc, Key Employees 69

Emergent BioSolutions Inc, Other Locations 70

Emergent BioSolutions Inc, Subsidiaries 70

Emergent BioSolutions Inc, Joint Venture 72

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Emergent BioSolutions Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.